Design, synthesis and biological evaluation of novel nitroaromatic compounds as potent glutathione reductase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 18, 2011, Pages 5398-5402

  Akmak, Reit ^a,b   Durdagi, Serdar ^c   Ekinci, Deniz ^d   Entürk, Murat ^e   Topal, Giray ^a,b  

^a BATMAN UNIVERSITY   (Turkey)

^b DICLE UNIVERSITY   (Turkey)

^c UNIVERSITY OF CALGARY   (Canada)

^d ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^e AGRI IBRAHIM CECEN UNIVERSITY   (Turkey)

Author keywords

Antimalaria; Glutathione reductase; In silico docking; Nitroaromatic

Indexed keywords

AROMATIC NITRO COMPOUND; ESSENTIAL AMINO ACID; GLUTAMIC ACID; GLUTATHIONE REDUCTASE; LYSINE; N 4 NITROBENZOYL 2 AMINO 1 BUTHANOL; N 4 NITROBENZOYL GLUTAMIC ACID; N ALPHA BOC N EPSILON 2 CHLORO BENZYLOXYCARBONYL LYSINE 4 NITROPHENYLESTER; NIFEDIPINE; OXIDOREDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG SCREENING; DRUG SYNTHESIS; IC 50; MOLECULAR DOCKING; MOLECULAR INTERACTION;

CHEMISTRY TECHNIQUES, SYNTHETIC; CRYSTALLOGRAPHY, X-RAY; DINITROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; ENZYME INHIBITORS; GLUTATHIONE REDUCTASE; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80051932732     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.002     Document Type: Article

References (29)

1. A. Meisler, and M.E. Anderson Ann. Rev. Biochem. 52 1983 711
2. M. Gul, F.Z. Kutay, S. Temocin, and O. Hanninen Indian J. Exp. Biol. 38 2000 625
3. R.H. Schirmer, R.L. Krauth-Siegel, and G.E. Schulz D. Dolphin, R. Poulson, O. Avramovic, Coenzymes and Cofactors Vol. 3A 1989 John Wiley and Sons New York 553 596
4. N. Chavain, E. Davioud-Charvet, X. Trivelli, L. Mbeki, M. Rottmann, R. Brun, and C. Biot Bioorg. Med. Chem. 17 2009 8048
5. WHO. Guidelines for the Treatment of Malaria. 2010, 2nd edition.
6. H. Ginsburg, O. Famin, J. Zhang, and M. Krugliak Biochem. Pharmacol. 56 1998 1305
7. H. Atamna, and H. Ginsburg J. Biol. Chem. 270 1995 24876
8. R.H. Schirmer, J.G. Müller, and R.L. Krauth-Siegel Angew. Chem., Int. Ed. 34 1995 141
9. S. Meierjohan, R.D. Walter, and S. Müller Biochem. J. 368 2002 761
10. M. Senturk, O.I. Kufrevioglu, and M. Ciftci J. Enzyme Inhib. Med. Chem. 23 2008 144
11. M. Senturk, I. Gulcin, M. Ciftci, and O.I. Kufrevioglu Biol. Pharm. Bull. 31 2008 2036
12. M. Senturk, O.I. Kufrevioglu, and M. Ciftci J. Enzyme Inhib. Med. Chem. 24 2009 420
13. E. Akkemik, M. Senturk, F.B. Ozgeris, P. Taser, and M. Ciftci Turk. J. Med. Sci. 41 2011 235
14. E. Davioud-Charvet, S. Delarue, C. Biot, B. Schwobel, C.C. Boehme, A. Mussigbrodt, L. Maes, C. Sergheraert, P. Grellier, R.H. Schirmer, and K. Becker J. Med. Chem. 44 2001 4268
15. M. Senturk, O. Talaz, D. Ekinci, H. Cavdar, and O.I. Kufrevioglu Bioorg. Med. Chem. Lett. 19 2009 3661
16. C. Alp, D. Ekinci, M.S. Gultekin, M. Senturk, E. Sahin, and O.I. Kufrevioglu Bioorg. Med. Chem. 18 2010 4468
17. T.A. Coban, M. Senturk, M. Ciftci, and O.I. Kufrevioglu Protein Peptide Lett. 14 2007 1027
18. A.H. Fairlamb, P. Blackburn, P. Ulrich, B.T. Chait, and A. Cerami Science 227 1985 1485
19. V. Massey, and C.H. Williams J. Biol. Chem. 240 1965 4470
20. J. Arning, R. Dringen, M. Schmidt, A. Thiessen, S. Stolte, M. Matzke, U. Bottin-Weber, B. Caesar-Geertz, B. Jastorff, and J. Ranke Toxicology 246 2008 203
21. P. Grellier, J. Sarlauskas, Z. Anusevicius, A. Maroziene, C. Houee-Levin, J. Schrevel, and N. Cenas Arch. Biochem. Biophys. 393 2001 199
22. N.K. Cenas, D.A. Bironaite, J.J. Kulys, and N.M. Sukhova Biochim. Biophys. Acta 1073 1991 195
23. P.A. Karplus, E.F. Pai, and G.E. Schulz Eur. J. Biochem. 178 1989 693
24. D. Cioli, C. Valle, F. Angelucci, and A.E. Miele Trends Parasitol. 24 2008 379
25. 19 Schrodinger's IFD protocol model uses the following steps (the description below is from the IFD user manual): (i) Constrained minimization of the receptor with an RMSD cutoff of 0.18. (ii) Initial Glide docking of each ligand using a soft potentials (0.8 van der Waals radii scaling of non-polar atoms of ligands and receptor using partial charge cutoff of 0.15). (iii) Refinement of the docking poses was done using the Prime module of Schrodinger. Residues within 5.0 of ligand poses were minimized in order to form suitable conformations of poses at the active site of the receptor. (iv) Glide redocking of each protein-ligand complexes.
26. I. Carlberg, and B. Mannervik J. Biol. Chem. 250 1975 5475
27. M.M. Bradford Anal. Biochem. 72 1976 248
28. U.K. Laemmli Nature 227 1970 680
29. H. Lineweaver, and D. Burk J. Am. Chem. Soc. 57 1934 685